RecruitingPhase 4NCT06411028

Factors Determining the Efficacy of Botulinum Toxin for Arm Tremor in Dystonia

Factors Determining the Efficacy of Botulinum Toxin for Arm Tremor in Dystonia: An Exploratory Study


Sponsor

Radboud University Medical Center

Enrollment

60 participants

Start Date

Jan 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Tremor occurs in up to 55% of dystonia patients, which is known as dystonic tremor syndrome (DTS). Tremor can be present in the body part affected by dystonia (dystonic tremor, DT), or an unaffected body part (tremor associated with dystonia, TAWD). DTS can be treated with botulinum neurotoxin (BoNT) injections, but BoNT is effective in only about 60-70% of patients. It is unknown which patients benefit most from BoNT treatment. The investigators aim to explore the associations between clinical and pathophysiological tremor characteristics and BoNT efficacy. To do so, the investigatorswill measure clinical, electrophysiological, ultrasonographic and (functional) magnetic resonance imaging ((f)MRI) characteristics before the start of BoNT treatment and measure BoNT efficacy after three three-monthly BoNT sessions.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Clinical diagnosis of dystonic tremor or tremor associated with dystonia according to the 2018 consensus statement on the classification of tremors
  • Tremor of one or both upper extremities
  • Starting botulinum toxin injections as part of normal clinical practice
  • Age ≥ 18 years

Exclusion Criteria14

  • Acquired aetiology of dystonic tremor syndrome
  • Previous botulinum toxin treatment of the to be treated upper extremity for ≥ 4 consecutive sessions
  • In case of previous botulinum toxin treatment of the to be treated upper extremity for ≤3 consecutive sessions: the last botulinum toxin injections ≤ 6 months before study enrolment
  • Unstable dose medications for dystonia and tremor ≤ 1 month before study enrolment
  • Deep brain stimulation implantation ≤ 6 months before study enrolment
  • Unstable deep brain stimulation variables ≤ 1 month before study enrolment
  • Comorbidity interfering with study participation
  • Known hypersensitivity for components of Dysport
  • Infection at the upper extremity
  • Pregnancy, trying to conceive and breastfeeding
  • Insufficient knowledge of the Dutch or English language
  • Contraindications for MRI (e.g. previous brain surgery, claustrophobia, active implant, epilepsy, metal objects in the upper body that are incompatible with MRI)
  • Moderate to severe head tremor while lying supine (to avoid artefacts caused by extensive head motion during scanning).
  • Inability to provoke postural tremor while lying supine.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTPolymyography

We will measure muscle activity using surface electromyography and tremor using inertial measurement units while subjects perform rest, posturing and kinetic tasks.

DIAGNOSTIC_TESTMuscle ultrasound

We will obtain B-mode images and videos of upper extremity muscles of the most affected upper extremity.

DIAGNOSTIC_TEST(Functional) magnetic resonance imaging

Subjects will undergo (f)MRI scanning involving concurrent electromyography, accelerometry and functional magnetic resonance imaging.

DIAGNOSTIC_TESTClinical assessment

We will assess tremor and dystonia severity using clinical scales.

DIAGNOSTIC_TESTQuestionnaires

We will collect patient-reported outcomes.

DRUGbotulinum toxin injection (BTX A)

Three consequetive botulinum toxin injections of the upper extremities


Locations(3)

Donders Centre for Cognitive Neuroimaging

Nijmegen, Gelderland, Netherlands

Radboud University Medical Center

Nijmegen, Gelderland, Netherlands

Canisius-Wilhelmina Ziekenhuis

Nijmegen, Gelderland, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06411028